Modernising haematological malignancy adverse event assessment and reporting

Targeted agents, immune and cellular therapies and other novel agents have led to dramatic shifts in the treatment of many hematologic malignancies (HM). These therapies bear toxicities that are unique, chronic or delayed relative to conventional chemotherapies. Many are administered for months to years, impacting treatment tolerability over time. In this context, a global, multi-disciplinary Lancet Haematology Adverse Events (AE) Commission comprised of patient advocates, clinical investigators, regulators and other stakeholders was assembled to examine and propose solutions to modernize AE assessment. In this webinar, Commission leads will update key priorities in improving AE evaluation with a focus on patients with HM not only living longer but living better. Presenters: Gita Thanarajasingam, Mayo Clinic, USA Amylou Dueck, Mayo Clinic, USA Lori Minasian, the US National Cancer Institute (NCI), USA Surbhi Sidana, Stanford University, USA Karin Ekstrom-Smedby, Karolinska Institutet, Sweden Nicole Gormley, U.S. Food and Drug Administration (FDA), USA Tarec Christoffer El-Galaly, Aalborg University Hospital, Denmark